Drug intelligence / Profile preview

AGV07

Development stage: Preclinical
Lead developer: AGV Discovery
Modality: Small Molecules

Overview

AGV07 is an early-stage small molecule drug candidate being developed by AGV Discovery for the treatment of various cancers. Currently in the target identification phase of preclinical development, the compound is being designed using the company's Fragment Based Drug Design (FBDD) platform. AGV Discovery focuses on identifying novel oncology targets, often in collaboration with research centers such as the Montpellier Research Centers, with a specific interest in cancer stem cells and circulating tumor cells in advanced colorectal cancers.

Beyond the preview

Go deeper on AGV07.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AGV07.

Explore the full profile